Biogen slashes price of controversial Alzheimer's drug
After a slow start for its Alzheimer's treatment, Aduhelm, US-based Biogen is attempting to kick-start sales by halving the price.
by marketwire, translated by catherine brett
US-based Biogen has dropped the price of its Alzheimer's treatment Aduhelm by fifty percent, Bloomberg News reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen's Aduhelm rejected by EMA committee
For subscribers
